Merck's Keytruda shows mixed results in phase 3 trial for small cell lung cancer

Merck& Co said a phase 3 trial of cancer drug Keytruda in combination with chemotherapy showed an increase in  the amount of time patients lived with small cell lung cancer without it getting worse, but did not extend overall survival.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news